Prediction Case File
YouTubeEvaluation Complete

UnitedHealth is having a challenging year in 2025, but investors are hopeful 2026 will be much better.

1 extracted signal · 1 resolved · 0 still active

Parkev Tatevosian, CFA profile imageParkev Tatevosian, CFAIndependent analyst profile
Source published
29 Aug 2025, 21:45 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for UnitedHealth is having a challenging year in 2025, but investors are hopeful 2026 will be much better.
Source overview

AI-generated source summary

The analysis discusses United Health's difficult year and predicts a stock price range of $400-$430 by the end of 2026, based on a $21.74 EPS estimate for 2027, with data from Fiscal.ai. The current forward P/E is 18.92. Scenarios presented involve different forward P/E ratios. Investors might reward the firm once margins improve. The highest estimated price is $543.50, corresponding to a forward P/E of 25. The fail bound is set at $250.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
1
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
100%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

Parkev Tatevosian, CFA

Platform-wide history, separate from this source evaluation.

Reliability
41.8
Tracked signals
1293
Historical success
25.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail